227
Participants
Start Date
September 16, 2019
Primary Completion Date
April 2, 2024
Study Completion Date
September 9, 2024
Adalimumab (ADA)
Adalimumab is a fully-human monoclonal antibody to TNF-α, which is approved by the U.S. FDA for the treatment of non-infectious intermediate, posterior, and panuveitides in adults and children 2 years of age and older.
Conventional immunosuppression (CON)
The study ophthalmologist will select amongst the permissible drugs (methotrexate, mycophenolate mofetil or azathioprine for antimetabolites; cyclosporine or tacrolimus for calcineurin inhibitors) taking into account the side effect profile of each drug with respect to subject's clinical situation.
University of Pittsburgh Medical Center, Pittsburgh
MidAtlantic Retina, Wills Eye Hospital, Philadelphia
National Eye Institute, Bethesda
Johns Hopkins University, Baltimore
Emory University, Atlanta
Anne Bates Leach Eye Hospital, University of Miami Miller School of Medicine, Miami
Tennessee Retina, Nashville
Vanderbilt University Eye Institute, Nashville
University of Michigan Health System, Kellogg Eye Center, Ann Arbor
University of Iowa, Iowa City
Northwestern University, Chicago
Rush University Medical Center, Chicago
Washington University, St Louis
Retinal Consultants of Texas, Bellaire
University of Utah, Moran Eye Center, Salt Lake City
Jules Stein Eye Institute, UCLA, Los Angeles
University of California, San Francisco, San Francisco
University of Washington, Medicine Eye Institute, Seattle
Ophthalmic Consultants of Boston, Boston
Centre for Eye Research Australia, East Melbourne
University of Sydney, Sydney
Bradford Teaching Hospital NHS Foundation Trust, Bradford
University Hospital Birmingham, Edgbaston
Cambridge University NHS Trust, Cambridge
University Hospitals of Leicester, Leicester
Moorfields Eye Hospital NHS Foundation Trust, London
Lead Sponsor
JHSPH Center for Clinical Trials
OTHER